A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab
plus Iplimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (CheckMate 649: CHECKpoint pathway and nivoluMab Clinical Trial Evaluation 649), NCT02872116
PURPOSE OF THIS CLINICAL RESEARCH TRIAL
The main purpose of this study is to compare how long patients with gastric or gastroesophageal junction cancer live after receiving nivolumab and ipilimumab or nivolumab and chemotherapy compared with patients receiving chemotherapy alone.
MORE DETAILS ON THIS GASTROINTESTINAL CANCER TRIAL
16164 / CA209649 / NCT02872116 / Re-Open 12-10-2018
TRIAL AVAILABLE AT THESE LOCATIONS